ALMS — ALUMIS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1847367 ·
Last close
$23.03
Market Cap
$2.98B
52W High
$31.35
52W Low
$18.36
ADV30
973,493
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,741,000 | — | -98,409,000 | -93,053,000 | 671,588,000 | 63,885,000 | 104,567,000 |
| Dec 2025 | 1,929,000 | — | -96,445,000 | -92,931,000 | 411,940,000 | 89,670,000 | 110,643,000 |
| Sep 2025 | 2,066,000 | — | -115,292,000 | -110,752,000 | 488,014,000 | 65,257,000 | 103,241,000 |
| Jun 2025 | 2,666,000 | — | -140,539,000 | 59,321,000 | 610,925,000 | 151,753,000 | 125,598,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-376,250,000
Investing CF
$-37,237,000
Financing CF
$349,055,000
CapEx
$-1,183,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.05
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-994,929,000
Inventory
—
Receivables
$2,730,000
ST Investments
$459,058,000
EBIT TTM
$-450,685,000
Pretax Income TTM
$-245,976,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,398,000
EBITDA
$-421,448,992
Free Cash Flow
$-208,637,632
Enterprise Value
$2,515,027,456
Total Cash
$502,292,992
Total Debt
$36,427,000
Shares Out
129,435,239
Trailing EPS
$-3.92
Book Value
$3.52
ROE
-93.6%
ROA
-45.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 24,050,000 | -453,804,000 | -243,325,000 | 411,940,000 | 110,643,000 | — | -369,523,000 |
| Dec 2024 | 0 | -300,754,000 | -294,233,000 | 340,992,000 | 80,888,000 | — | -255,078,000 |
| Dec 2023 | 0 | -158,174,000 | -154,993,000 | 89,612,000 | 428,872,000 | — | -129,975,000 |
| Dec 2022 | 0 | -113,850,000 | -111,930,000 | 108,168,000 | 303,410,000 | — | -107,722,000 |
TTM Snapshot
Revenues TTM
$2,066,000
NetIncome TTM
$-136,494,000
OpCashFlow TTM
$0
Assets (Latest)
$340,992,000
Forward EPS
$-2.87
Max Pain — expiry 2026-09-18
max pain strike: $27.00 · spot: $23.57 · call oi: 27,731 · put oi: 15,070
Expected Move to 2026-09-18:
±$12.45
(52.82%) —
implied range
$11.12 –
$36.02
· ATM straddle on $24.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLS | SELLAS Life Sciences Group, Inc. | $2.89B | $14.32 | — |
| ZLAB | Zai Lab Ltd | $2.88B | $25.64 | — |
| IRON | Disc Medicine, Inc. | $3.11B | $80.94 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.11B | $24.78 | — |
| IMNM | Immunome Inc. | $3.18B | $28.01 | — |
News headlines (Yahoo Finance, 1h cache)
Stifel and Guggenheim Stay Bullish on Alumis (ALMS)
2026-07-01 21:23 · Yahoo
Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements
2026-05-29 10:31 · Yahoo
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
2026-05-24 14:33 · Yahoo
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?
2026-05-20 04:34 · Yahoo
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
2026-05-17 18:33 · Yahoo
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
2026-05-15 22:56 · Yahoo
A Look At Alumis (ALMS) Valuation After Revenue Drop And Narrowed Net Loss
2026-05-15 03:17 · Yahoo
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
2026-05-14 20:05 · Yahoo
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
2026-05-10 09:53 · Yahoo
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
2026-08-13 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.